BPC-157 — - 10mg

BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a partial sequence of a human gastric juice protein known as Body Protection Compound (BPC), from which its name is derived. This peptide has garnered significant interest within the research community due to its remarkable stability and pleiotropic biological activities observed in a wide range of preclinical models. Unlike many endogenous peptides that degrade rapidly in the gastrointestinal tract, BPC-157 exhibits unusual stability, making it a robust subject for in vitro and in vivo laboratory investigations.

The peptide's molecular structure, with a molecular weight of 1419.5 g/mol, is central to its function. Its sequence does not conform to a typical signaling peptide motif, and it notably lacks a specific, high-affinity receptor identified to date. This suggests that its mechanism of action may be unconventional, possibly involving the modulation of multiple downstream pathways or direct interaction with cellular components like growth factor receptors or cytoskeletal proteins. This unique characteristic has made BPC-157 a compelling tool for researchers exploring novel mechanisms of tissue repair, cytoprotection, and homeostatic regulation.

In laboratory settings, BPC-157 has been investigated for a broad spectrum of potential applications, including the study of musculoskeletal injuries, gastrointestinal pathologies, and neurological insults. Its capacity to influence angiogenesis, modulate nitric oxide signaling, and interact with various growth factor pathways has been a primary focus of study. Researchers utilize BPC-157 to probe the fundamental cellular and molecular processes underlying tissue regeneration and the body's intrinsic repair systems. As a research-grade compound, it provides a standardized tool for exploring these complex biological phenomena. All products supplied by Nexa Peptides, including BPC-157, are intended strictly for in vitro research and laboratory use only and are not for human or animal consumption.

The mechanism of action for BPC-157 is multifaceted and appears to be mediated through the modulation of several key signaling pathways rather than binding to a single, specific receptor. A central aspect of its activity observed in research models is its profound influence on angiogenesis, the formation of new blood vessels. Studies indicate that BPC-157 can upregulate the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). The activation of VEGFR2 initiates downstream signaling cascades, including the FAK-paxillin and PI3K/Akt/eNOS pathways. The Focal Adhesion Kinase (FAK) and paxillin are critical components of focal adhesions, which mediate cell adhesion and migration. By activating this axis, BPC-157 is thought to promote endothelial cell migration and proliferation, essential steps in angiogenesis.

Simultaneously, the activation of the PI3K/Akt pathway leads to the phosphorylation and activation of endothelial Nitric Oxide Synthase (eNOS). This increases the production of nitric oxide (NO), a potent vasodilator and signaling molecule that enhances blood flow and vessel permeability, further supporting tissue repair. The ability of BPC-157 to modulate the NO system is a hallmark of its activity; it has been shown to normalize NO levels in conditions of both over- and under-production, suggesting a homeostatic regulatory role. This effect is crucial for maintaining endothelial integrity and responding to ischemic or inflammatory insults in experimental models.

BPC-157's cytoprotective effects are also linked to its interaction with the cellular cytoskeleton. Research suggests it can promote the reorganization of F-actin in fibroblasts, enhancing their structural integrity and migratory capacity. This cytoskeletal stabilization is thought to contribute to its observed effects on tendon and ligament healing in animal models, where organized collagen deposition and tissue strength are paramount. Furthermore, BPC-157 has been investigated for its ability to counteract the damaging effects of various toxins and stressors, such as NSAIDs in gastric tissue models. This protection is partly attributed to its ability to maintain epithelial barrier function and reduce inflammatory responses.

In addition to these pathways, BPC-157 may modulate the activity of various growth factors. Some studies suggest it can influence the expression or signaling of Nerve Growth Factor (NGF) and Epidermal Growth Factor (EGF), contributing to its neuroprotective and wound-healing properties observed in preclinical research. From an anti-inflammatory perspective, BPC-157 has been shown to attenuate the expression of pro-inflammatory cytokines like TNF-α and IL-6 in certain inflammatory models. This complex interplay of pro-angiogenic, cytoprotective, and anti-inflammatory signaling pathways makes BPC-157 a subject of intense investigation for understanding endogenous repair mechanisms. For Research Use Only.

BPC-157 is a versatile peptide utilized across multiple domains of biomedical research, primarily focusing on tissue repair, cytoprotection, and anti-inflammatory mechanisms. A significant body of preclinical research has been conducted in the field of musculoskeletal science. In various rodent models of injury, such as tendon transection, ligament damage, and muscle contusion, researchers have investigated the effects of BPC-157 administration on healing outcomes. These studies often assess parameters like collagen fiber organization via histology, tensile strength of repaired tissues, and functional recovery rates. The objective of such research is to elucidate the molecular pathways, like the FAK-paxillin axis, that govern the repair of connective tissues.

Given its origins from a gastric protein, gastroenterology is another primary area of investigation. BPC-157 has been extensively studied in animal models of gastrointestinal pathology. This includes research into NSAID-induced gastric lesions, where its cytoprotective properties are examined, and models of Inflammatory Bowel Disease (IBD), where its anti-inflammatory and barrier-protective functions are explored. Researchers use these models to understand how BPC-157 might mitigate mucosal damage, promote ulcer healing, and maintain the integrity of the gastrointestinal epithelial barrier.

In cardiovascular research, BPC-157 has been employed in models of ischemia-reperfusion injury and peripheral artery disease. Investigations focus on its pro-angiogenic effects, mediated by the VEGF/VEGFR2 pathway, and its ability to modulate the nitric oxide system. Studies in rodent models with induced hindlimb ischemia, for instance, are used to evaluate its potential to stimulate collateral vessel formation and restore blood flow to compromised tissues. These experiments provide insights into peptide-mediated regulation of endothelial function and vascular homeostasis.

Neurological research represents another frontier for BPC-157 investigations. Preclinical studies using models of traumatic brain injury (TBI), spinal cord injury, and chemically induced neurotoxicity have explored its neuroprotective potential. Researchers assess its effects on neuronal survival, glial scarring, and the modulation of neurotransmitter systems, such as the dopaminergic and serotonergic systems. These studies aim to uncover novel mechanisms for protecting neural tissue from secondary injury cascades and promoting functional recovery in controlled laboratory settings. All applications of BPC-157 are strictly for in vitro laboratory and preclinical research purposes. Not for human use.